Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...

Level up your trading with BMO InvestorLine’s enhanced features

With about 48 per cent of Canadians investing regularly, according to an Ipsos poll conducted in February, and more young people learning about the benefits of putting money to work than ever before, the demand for leading-edge trading platforms in terms of efficienc...

Buzz on the Bullboards: Despite energy woes, TSX hits new high

This week, the TSX endured fluctuations but ultimately achieved a new high in intraday trading. The tech sector has been a significant driver of these gains, thanks to a solid performance among top stocks in the sector. One of Canada’s leading te...

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. In a June 16 research note, ROTH Capital Partners analyst Scott Henry reported that Beyond Air Inc. (XAIR:NASDAQ) enrolled the first patient in its U.S. clin...

Opportunity Knocks as the Door Opens to Naturally-Derived Psychedelics

(CLICK IMAGE TO PLAY VIDEO) Stockhouse investors know that investment opportunities are opening up in the burgeoning psychedelics space. And while many are called, few are chosen. One company that looks to be the choice of many in the know is Filament Health Co...

Tick-Tock: Quietly Doing the Work Proving an Intriguing Gold Resource

When we first talked about Tocvan Resources ( TOC.C , Forum ) back in June, it was selling for around $0.15 and nobody was really talking about it. In certain markets, hype is rewarded hard, but there's something to be said for a deal in which what's being said is the v...

Buzz on the Bullboards: New Rising Opportunities

There has been a lot of attention on the tech sector and the stocks working in that marketplace as of late. Despite market volatility, the tech-heavy Nasdaq has displayed much growth this year as it dug itself out of the COVID hole that had investors and the markets at large p...
1 2 3 4 5 6 7 8 9 10 ...